These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31766279)

  • 41. An update in treatment options for multiple myeloma in nontransplant eligible patients.
    Broijl A; Sonneveld P
    Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunomodulatory drugs in the treatment of multiple myeloma.
    Abe Y; Ishida T
    Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overcoming proteasome inhibitor resistance in the immunotherapy era.
    Patiño-Escobar B; Talbot A; Wiita AP
    Trends Pharmacol Sci; 2023 Aug; 44(8):507-518. PubMed ID: 37344251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exosome-Transmitted
    Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
    Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New insights into therapeutic targets in myeloma.
    Anderson KC
    Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
    Qiang YW; Ye S; Huang Y; Chen Y; Van Rhee F; Epstein J; Walker BA; Morgan GJ; Davies FE
    BMC Cancer; 2018 Jul; 18(1):724. PubMed ID: 29980194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Cheriyath V; Jacobs BS; Hussein MA
    Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel targeted therapies and combinations for the treatment of multiple myeloma.
    Agarwal A; Mahadevan D
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibodies in myeloma.
    Sondergeld P; van de Donk NW; Richardson PG; Plesner T
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):599-609. PubMed ID: 26452191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoclonal antibody therapy in multiple myeloma.
    Touzeau C; Moreau P; Dumontet C
    Leukemia; 2017 May; 31(5):1039-1047. PubMed ID: 28210004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
    Le Ray E; Jagannath S; Palumbo A
    Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Drugs in Multiple Myeloma.
    Kunacheewa C; Orlowski RZ
    Annu Rev Med; 2019 Jan; 70():521-547. PubMed ID: 30691369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
    Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
    Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.
    Willenbacher W; Seeber A; Steiner N; Willenbacher E; Gatalica Z; Swensen J; Kimbrough J; Vranic S
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30021955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.
    Thomas AL; Coarfa C; Qian J; Wilkerson JJ; Rajapakshe K; Krett NL; Gunaratne PH; Rosen ST
    Nucl Recept Signal; 2015; 13():e006. PubMed ID: 26715915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review).
    Krishnan SR; Jaiswal R; Brown RD; Luk F; Bebawy M
    Int J Oncol; 2016 Jul; 49(1):33-50. PubMed ID: 27175906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
    Fuchs O
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):16-34. PubMed ID: 23534949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.